CN101991665A - Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof - Google Patents
Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof Download PDFInfo
- Publication number
- CN101991665A CN101991665A CN2010105515684A CN201010551568A CN101991665A CN 101991665 A CN101991665 A CN 101991665A CN 2010105515684 A CN2010105515684 A CN 2010105515684A CN 201010551568 A CN201010551568 A CN 201010551568A CN 101991665 A CN101991665 A CN 101991665A
- Authority
- CN
- China
- Prior art keywords
- tumor
- myrrha
- olibanum
- water
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 82
- 208000031229 Cardiomyopathies Diseases 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 title abstract description 19
- 230000017074 necrotic cell death Effects 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 39
- 241001489978 Eupolyphaga Species 0.000 claims abstract description 33
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims abstract description 20
- 229940097275 indigo Drugs 0.000 claims abstract description 20
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004863 Frankincense Substances 0.000 claims abstract description 18
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229910052802 copper Inorganic materials 0.000 claims abstract description 4
- 239000010949 copper Substances 0.000 claims abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 58
- 238000011282 treatment Methods 0.000 claims description 57
- 208000007875 Femur Head Necrosis Diseases 0.000 claims description 39
- 241000717739 Boswellia sacra Species 0.000 claims description 36
- 241001057584 Myrrha Species 0.000 claims description 36
- 229910052742 iron Inorganic materials 0.000 claims description 32
- 241000180649 Panax notoginseng Species 0.000 claims description 29
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 29
- 208000014192 neoplasm of femur Diseases 0.000 claims description 29
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 26
- 239000006187 pill Substances 0.000 claims description 26
- 239000008187 granular material Substances 0.000 claims description 22
- 239000003826 tablet Substances 0.000 claims description 22
- 239000000341 volatile oil Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000002552 dosage form Substances 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 14
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 13
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 13
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 11
- 241000235555 Cunninghamella Species 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 241000235556 Cunninghamella elegans Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000002054 inoculum Substances 0.000 claims description 6
- 239000012982 microporous membrane Substances 0.000 claims description 6
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 6
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 6
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 241000590020 Achromobacter Species 0.000 claims description 4
- 241001290628 Cunninghamella echinulata Species 0.000 claims description 4
- 241000589565 Flavobacterium Species 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 3
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 240000005373 Panax quinquefolius Species 0.000 claims description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000003517 fume Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 229940099596 manganese sulfate Drugs 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 241000193755 Bacillus cereus Species 0.000 claims description 2
- 239000011684 sodium molybdate Substances 0.000 claims 1
- 235000015393 sodium molybdate Nutrition 0.000 claims 1
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 21
- 210000004369 blood Anatomy 0.000 abstract description 21
- 230000001737 promoting effect Effects 0.000 abstract description 17
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 230000017423 tissue regeneration Effects 0.000 abstract description 8
- 230000006870 function Effects 0.000 abstract description 5
- 206010028851 Necrosis Diseases 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000001502 supplementing effect Effects 0.000 abstract description 3
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 abstract 1
- 241000227129 Aconitum Species 0.000 abstract 1
- 208000030016 Avascular necrosis Diseases 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 206010031264 Osteonecrosis Diseases 0.000 abstract 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 229940023488 pill Drugs 0.000 description 24
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 15
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 15
- 210000001624 hip Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000004217 heart function Effects 0.000 description 11
- 241000333074 Eucalyptus occidentalis Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
- 229960002949 fluorouracil Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 230000001338 necrotic effect Effects 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000009877 shengmai Substances 0.000 description 5
- 230000037180 bone health Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010047470 viral myocarditis Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 230000003680 myocardial damage Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 108010048734 sclerotin Proteins 0.000 description 3
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000004394 hip joint Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940100691 oral capsule Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 206010002027 Amyotrophy Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000015813 Familial avascular necrosis of femoral head Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002371 cardiac agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000008407 joint function Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007483 microbial process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- -1 vaccine Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a composition for treating myocardial diseases, femoral head necrosis and a tumor, which comprises the following raw material medicaments in parts by weight: 10 to 150 parts of panax pseudoginseng, 20 to 200 parts of gen-seng, 10 to 100 parts of frankincense, 10 to 100 parts of myrrh, 10 to 150 parts of eupolyphaga, 10 to 150 parts of keel, 5 to 100 parts of natural copper, 1 to 10 parts of artificial musk, 10 to 150 parts of aconitum szechenyianum, 10 to 120 parts of bryozoatum and 5 to 150 parts of indigo. The invention also discloses a preparation process of the composition. The composition has the functions of supplementing qi, promoting blood circulation for removing blood stasis, strengthening body resistance and eliminating evil, and removing blood stasis for promoting tissue regeneration, and can simultaneously treat the myocardial diseases, avascular necrosis diseases of the femoral head and inhibit the tumor.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation technology thereof, relate in particular to the compositions and the preparation technology thereof of treatment cardiomyopathy, femur head necrosis and tumor.
Background technology
From up-to-date data at home and abroad, still lack good treatment medicine of imitating at cardiomyopathy (viral myocarditis, DCM (dilated cardiomyopathy), coronary heart disease etc.), viral myocarditis is sure to occupy the 4th (10.8%) of heart sickness rate.Whole primary cardiac and in, DCM (dilated cardiomyopathy) accounts for 90%.Yet, at the new drug of two-way treatment viral myocarditis and DCM (dilated cardiomyopathy), mainly concentrating in the research and development of some medicines such as vaccine, immunosuppressant and interferon at present, these medicines not only cost an arm and a leg, and its therapeutic evaluation is still had a question.Chinese medicinal formulae because have concurrently anti-set upright get rid of evils, many-sided effects such as blood stasis dispelling and blood stasis dispelling, and be applied to clinical treatment for many years, curative effect is sure.Femur head necrosis, also be ischemic necrosis of femoral head, aseptic necrosis of femoral head, it is the difficult disease that pathogenesis is failed to understand and is difficult to cure in the present world wide, its pathological process be since during disturbance of blood circulation blood supply be obstructed, thereby make active component (bone, the adipose cell in marrow) death of femoral head sclerotin.On modern medicine, be called as " not dead cancer ".Still the infallible medicine of inefficacy can be cured femur head necrosis at present.Blood circulation promoting and blood stasis dispelling, promoting tissue regeneration by removing blood stasis etc. are many-sided to be acted on and Chinese medicinal formulae is because have concurrently, can be to suppressing the state of an illness, and alleviating pain plays good effect.And on the other hand, tcm prescription is at the characteristics of the sick disease of tumor middle and advanced stage " deficiency of vital energy and blood stasis ", suppress tumor and collaboratively put, the aspect of the immunity of chemotherapeutic treatment tumor and enhancing and adjusting body plays good effect.Motherland's medical science is thought: the generation of cardiomyopathy, ischemic necrosis of femoral head and tumor, having some common pathogenesis comprises: the deficiency of vital energy, blood stasis, evil poison and the resistance of becoming silted up, three kinds of diseases all can be owing to the evil poison of diseases caused by exogenous pathogenic factor, cause human body imbalance between YIN and YANG, internal organs meridian function not normal, with the passing of time deficiency of qi and blood, the deficiency of vital energy then to promote blood capable unable, and then blood stasis appears, accumulate in the evil in addition poison, finally cause the formation of kinds of tumors in myocardial damage (function is impaired and dead), sclerotin injury (necrosis) and even the body.For this reason, at above-mentioned three kinds of common mechanism of disease, traditional Chinese medical science compositions can play certain therapeutical effect to three kinds of diseases simultaneously according to itself multicomponent, many target spots, multi-level holistic medicine pattern.
At the existing granted patent (ZL00131516.X of the compositions of cardiomyopathy, a kind of compositions for the treatment of cardiomyopathy, the patentee is the inventor), but said composition only can be treated cardiomyopathy, can't treat cardiomyopathy, femur head necrosis and three kinds of diseases of inhibition tumor simultaneously; Can not treat cardiomyopathy, femur head necrosis and inhibition tumor simultaneously and still there is other compositions at present yet.
Summary of the invention
Technical problem to be solved by this invention provides a kind of QI invigorating, blood circulation promoting and blood stasis dispelling, sets upright the silt tissue regeneration promoting of getting rid of evils and dispel, the component Recipe rationally, curative effect treats the compositions of cardiomyopathy, femur head necrosis and tumor preferably.
Another technical problem to be solved by this invention provides the preparation technology of the said composition that a kind of technology is simple, flow process short, the effective ingredient extraction ratio is high.
For addressing the above problem, a kind of compositions for the treatment of cardiomyopathy, femur head necrosis and tumor of the present invention, it is characterized in that: said composition is made up of the following weight parts crude drug:
Radix Notoginseng 10～150 Radix Panacis Quinquefoliis 20～200 Olibanums 10～100 Myrrhas 10～100
Eupolyphaga Seu Steleophaga 10～150 Os Draconis 10～150 Pyritums 5～100 artificial Moschuss 1～10
Iron staff mallet 10～150 Pumexs 10～120 Indigo Naturaliss 5～150.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation of compositions technology of aforesaid treatment cardiomyopathy, femur head necrosis and tumor may further comprise the steps:
(1) measures each component by prescription;
(2) from Olibanum, Myrrha, extract Olibanum volatile oil, Myrrha volatile oil respectively; The mixture of described Olibanum volatile oil and described Myrrha volatile oil mixing back and beta-schardinger dextrin-and hydroxypropyl cellulose carries out inclusion by 8: 1 weight ratio to be fixed, obtain Olibanum-Myrrha clathrate, this Olibanum-Myrrha clathrate obtains relative density after concentrating be Olibanum-Myrrha extractum of 1～1.15; The weight ratio of wherein said beta-schardinger dextrin-and described hydroxypropyl cellulose is 1: 1;
(3) extract Pyritum and Pumex water-soluble extracting liquid:
Add the 100mL culture medium in 0.1g Pyritum coarse powder and 0.5g Pumex, and add antibacterial by the concentration of 3 * 108/mL, 10% inoculum concentration, making its pH value is 6.0～6.5; Be that 180r/min, temperature are to cultivate 15d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with described extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 20ml;
Wherein said culture medium is mixed by 1g potassium dihydrogen phosphate, 0.2g bitter salt, 1.3g dipotassium hydrogen phosphate, 0.02g calcium chloride, 1g ammonium nitrate, 0.1g three water iron chloride, 0.005g Zinc vitriol, 0.005g manganese sulfate, 0.005g bitter salt copper, 0.005g Sodium Molybdate Dihydrate, 0.1 gram Carnis Bovis seu Bubali cream, 0.3 gram peptone, 0.2 gram sodium chloride and 1L water;
(4) extract the Indigo Naturalis water-soluble extracting liquid:
After Indigo Naturalis is crushed to 200 orders, carries out inclusion with the mixture of beta-schardinger dextrin-and hydroxypropyl cellulose by 8: 1 weight ratio again and fix, obtain the Indigo Naturalis inclusion complex; The weight ratio of described beta-schardinger dextrin-and described hydroxypropyl cellulose is 1: 1;
In 0.5g Indigo Naturalis clathrate, add the 100mL culture medium, and by 3 * 10
6The concentration of individual/mL, 5% inoculum concentration add antibacterial, and making its pH value is 5.5～6.0; Be that 200r/min, temperature are to cultivate 10d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with described extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 50ml;
Wherein said culture medium is that 20% Rhizoma Solani tuber osi liquor, 3g potassium dihydrogen phosphate, 1.5g magnesium sulfate, 20g glucose, 18g agar and 1L water mix by the 200mL mass concentration;
(5) extract Eupolyphaga Seu Steleophaga extractum:
Being broken to behind 200 orders Eupolyph aga sinesis Walker with mass concentration is after 85% ethanol carries out reflux, extract,, and to obtain relative density be 1.15～1.35 Eupolyphaga Seu Steleophaga extractum through concentrating;
(6) preparation Os Draconis, iron staff mallet water soluble ingredient extractum:
After Os Draconis, iron staff mallet are mixed, after decocting, filter, concentrating, obtain relative density and be Os Draconis-iron staff mallet water soluble ingredient extractum of 1.15～1.25;
(7) Moschus, Radix Notoginseng, Radix Panacis Quinquefolii being ground to form particle diameter respectively is 200 purpose powder, and to Radix Notoginseng and Radix Panacis Quinquefolii ultraviolet disinfection;
(8) Os Draconis-iron staff mallet water soluble ingredient extractum of described step (6) gained, the Olibanum-Myrrha extractum of described step (2) gained, Pyritum and Pumex water-soluble extracting liquid, the Indigo Naturalis water-soluble extracting liquid of described step (4) gained, the Eupolyphaga Seu Steleophaga extractum of described step (5) gained of described step (3) gained are mixed with the Moschus powder of described step (7) gained and Notoginseng Root, the American Ginseng powder after the sterilization, obtain mixture; With this mixture routinely technology make tablet, capsule, granule, pill or electuary and get final product.
Olibanum volatile oil, Myrrha volatile oil in the described step (2) used petroleum ether dissolution after being meant and respectively Olibanum, Myrrha being crushed to 100 orders, and with Petroleum ether extraction volatile oil of volatilization petroleum ether gained in the water-bath fume hood again after colourless.
Antibacterial in the described step (3) is any one in achromobacter (Achromobacter sp), Flavobacterium (Flavobacterium sp), bacillus cereus (Bacillus sp), the excellent bacillus (Corynebacterium sp).
Antibacterial in the described step (4) is cunninghamella blakesleana AS 3.153 (Cunninghamella blakesleana.AS 3.153), cunninghamella blakesleana AS970 (Cunninghamella blakesleana.AS970), cunninghamella elegans AS 3.2028 (Cunninghamella elegans.AS 3.2028), cunninghamella elegans AS 3.156 (Cunninghamella elegans.AS 3.156), among the cunninghamella echinulata AS 3.2004 (Cunninghamella echinulata AS 3.2004) any one.
The decocting condition of described step (6) is meant that the feed liquid weight ratio is 1: 3～1: 5, decocts 3 times, is followed successively by 3h, 2h, 1h.
Monarch drug Radix Panacis Quinquefolii supplementing QI and nourishing YIN, strengthening vital QI to eliminate pathogenic factors, adjusting equilibrium between yin and yang in side's medicine of the present invention; The ministerial drug Radix Notoginseng, blood circulation promoting and blood stasis dispelling, eliminating blood stasis and smoothing collaterals, the foster flesh of invigorating blood circulation; And assistant has the effect of blood circulation and promoting silt tissue regeneration promoting, reparation damage with combinations such as Eupolyphaga Seu Steleophaga, iron staff mallet, Olibanum, Myrrha, Pyritums; The circulation of qi promoting of Moschus and Indigo Naturalis fragrance, push away blood and freely be messenger drug, all medicines share and play QI invigorating, blood circulation promoting and blood stasis dispelling altogether, set upright the effect of the silt tissue regeneration promoting of getting rid of evils and dispel.
Function cures mainly: have QI invigorating, blood circulation promoting and blood stasis dispelling, set upright the effect of the silt tissue regeneration promoting of getting rid of evils and dispel, can treat cardiomyopathy, ischemic necrosis of fermoral head and inhibition tumor simultaneously.
The present invention compared with prior art has the following advantages:
1, the present invention is from QI invigorating, blood circulation promoting and blood stasis dispelling, set upright this angle of silt tissue regeneration promoting of getting rid of evils and dispel and understand systematicly (viral myocarditis due to the myocardial damage again comprehensively, DCM (dilated cardiomyopathy) and coronary heart disease), sclerotin injury (necrosis) and blood stasis, tumor due to accumulateing in the evil poison, to treat the supplementing QI and nourishing YIN of myocarditis, methods and treatment blood stasis such as strengthening vital QI to eliminate pathogenic factors, the promoting blood circulation for tissue regeneration that accumulates in the evil poison, controlling silt collateral dredging method combines, thereby microcirculation improvement, the damage of reparation osseous tissue, anti peroxidation of lipid, remove free radical, reduce blood viscous, promote the Normocellular reparation of parafunctional myocardial cell or chemotherapy infringement, suppress tumor and collaborative putting, situations such as chemotherapeutic treatment tumor.
2, because the present invention adopts β-CD and hydroxypropyl cellulose (1: 1) inclusion to the volatile oil in Olibanum, the Myrrha, therefore, make medicine inclusion rate compared with prior art improve 2 times.
3, because the present invention adopts microbial process to extract Pyritum and Indigo Naturalis effective ingredient respectively, therefore, reduce the gastrointestinal tract pessimal stimulation of taking coarse Pyritum and Indigo Naturalis initiation widely, thereby strengthened the water solublity (greater than 300 times) of drug effect, improved bioavailability and curative effect.
4, preparation technology of the present invention is simple, flow process short.
5, the mensuration of side's medicine maximum tolerated dose of the present invention:
60 of mices, male and female half and half, disposable by irritating stomach suspension 0.4ml/10g of the present invention (animal capable tolerates the dose of Cmax and maximum volume), observe the mice active situation then and have or not death, continue 7 days, find that the mice ordinary circumstance is good, feed is normal, fur is bright and clean, and so none dead mouse is LD
50Can't measure; Its maximum tolerated dose is 36g/kg, is equivalent to about 500 times of clinical application amount, is very safe so side's medicine of the present invention uses.
Meanwhile, because the improvement of part technology, its maximum tolerated dose is brought up to 500 times for described 400 times from ZL00131516.X.
6, clinical experiment:
(1) use decoction for the treatment DCM (dilated cardiomyopathy) checking 60 example checkings of the present invention, the result is as follows:
Go into to organize patient and all meet the diagnostic criteria of WHO/ISFC in 1980 about DCM (dilated cardiomyopathy) through color ultrasonic diagnosis.Select cardiac function (by the USA New York NYHA of heart disease association cardiac functional grading) cardiac function II level 72 examples, III level 40 examples, IV level 8 examples; Atrial fibrillation 36 examples wherein, ventricular arrhythmia 84 examples amount to 120 routine dilated cardiomyopathy patients as the object of observation.Be divided into two groups at random.60 examples are organized in treatment, male 42 examples, women 18 examples; Minimum 24 years old of age, maximum 76 years old, average 50 years old; Matched group 60 examples, male 38 examples, women 21 examples; Minimum 20 years old of age, maximum 80 years old, average 50 years old.
Matched group SHENGMAI ZHUSHEYE 40mL+5% Glucose Liquid 250mL, quiet, 15～30/min, continuous 14d, the back continues to use 2 of SHENGMAI JIAONANG, oral, and three times on the one, digoxin 0.125g, captopril 0.125g are oral, and one day twice, 2 months courses of treatment.Oral capsule of the present invention is organized in treatment, and 2, oral, three times on the one.2 months courses of treatment, and be aided with digoxin simultaneously, captopril is oral.All do not use other cardiac drug and blood vessel dilating treatment before and after two groups of treatments in 2 months.Observe variation and treatment front and back cardiac function leading indicator (left ventricular ejection mark (LVEF), the myocardial enzymes (variation of lactic acid dehydrogenase (LDH), creatine phosphokinase indexs such as (CK) of two groups of clinical symptoms, cardiac function.
It is as follows to formulate the observe the curative effect standard: produce effects: clinical symptoms is obviously improved or is disappeared, and cardiac function improves 2 grades, and the left ventricular ejection mark increases 〉=25%, and myocardial enzymes reduces 〉=25%; Effectively: clinical symptom relief, cardiac function improves 2 grades, and the left ventricular ejection mark increases 〉=15%, and myocardial enzymes reduces 〉=15%; Invalid: clinical symptoms does not have improvement, and cardiac function does not have improvement even worsens.Observed result is referring to table 1, table 2:
Table 1 liang group curative effect comparative example (%)
Annotate: compare with matched group,
*P＜0.05.
Cardiac function relatively before and after the table 2 liang group treatment
Annotate: compare with matched group,
*P＜0.05.LDH normal value: 15～220IU/L, CK normal value 0～190IU/L.
Treat back total effective rate 86.67% with the present invention, and after the treatment, cardiac function leading indicator before and after the variation of contrast cardiac function and the treatment: left ventricular ejection mark (LVEF), (lactic acid dehydrogenase (LDH), creatine phosphokinase analyses such as (CK) show myocardial enzymes, show that index LVEF increase 〉=25%, myocardial enzymes CK, the LDH of myocardial function all has obvious reduction 〉=25%; Clinical symptoms takes a turn for the better.For investigating the therapeutic effect of the present invention to myocardial damage (DCM (dilated cardiomyopathy)), compare through clinical treatment and with commercially available SHENGMAI JIAONANG therapeutic effect and to do contrast, the result shows, of the present invention group of effective percentage height compared with SHENGMAI JIAONANG, effective percentage improves, the cardiac function leading indicator all is better than the SHENGMAI JIAONANG group, i.e. the present invention has therapeutical effect preferably.
(2) use decoction for the treatment femur head necrosis 12 example checkings of the present invention, the result is as follows:
Go into to organize patient and organize 12 examples, totally 18 hips are the male, and the oldest 72 years old, minimum 24 years old, average 48 years old.The course of disease is the longest 6 years, and is the shortest 2 months.Press Marcus by stages, I phases 5 hip, II phases 8 hip, III phases 3 hip, IV phases 3 hip.This group is mainly with clinical manifestation, X line, the CT diagnosis basis as primary disease.12 routine femur head necrosis patients all have hip pain in various degree, and pain increases the weight of when movable.The hip joint function change shows as spinfunction, flexing function limitation the earliest.6 examples are with in various degree limping, and 3 examples are suffered from the limb amyotrophy.
Matched group is with the strongly fragrant bone health of commercially available pellet pill capsule 10g, oral, three times on the one, three months courses of treatment.Oral capsule of the present invention is organized in treatment, and 2, oral, three times on the one.Three months courses of treatment.All do not use other class medicine simultaneously in 3 months before and after two groups of treatments.Observe leading indicators such as two groups of clinical symptoms, X line or CT, the result shows: suffer from symptoms such as limb pain, limping, hip joint motion is limited and significantly taken a turn for the better.Treat back total effective rate 89.36% with the present invention, and treatment back X line, CT examination result follow up a case by regular visits to I in 12 hips～II phase and have 2 hips to recover after 5～9 months in treatment, there is increase in density in various degree the visible necrotic area of X ray examination, and necrotic zone is before dwindled.The capable CT check of 6 hips, I～II phases 3 hip, wherein 2 hip necrotic areas before dwindle 40%.For investigating the therapeutic effect of the present invention to femur head necrosis, compare through clinical treatment and with the strongly fragrant bone health of commercially available pellet pill capsule therapeutic effect and to do contrast, the result shows that of the present invention group of effective percentage height compared with strongly fragrant bone health pill capsule, and effective percentage improves (89.36% → 72.67%); With the Follow-up results as a result of X line, CT examination after the treatment of control group: I in 12 hips～II phase has 1 hip to recover after 6～12 months in treatment, and there is increase in density in various degree the visible necrotic area of X ray examination, and necrotic zone is before dwindled.The capable CT check of 3 hips, I～II phases 2 hip, wherein 1 hip necrotic area before dwindles 20%.The present invention treats leading indicator and all is better than strongly fragrant bone health pill capsule group, i.e. the present invention has therapeutical effect preferably.
(3) side's medicine of the present invention suppresses the tumor evaluation test.
Present composition oral administration is to the test of cure effect of mice S180 sarcoma, and present composition oral administration is to people's pulmonary carcinoma A549 Nude Mice growth inhibited exercising result:
A, present composition oral administration are to mice S
180Growth of tumor has certain inhibitory action, and the suppression ratio during 20g/kg is 43.5～49.8%, and the suppression ratio during 10g/kg is 26.8～34.8%, and the suppression ratio during 5g/kg is 11.8～16.2%;
B, present composition 10g/kg associating 5-fluorouracil (5-FU) 12.5mg/kg obviously is better than individually dosed to the tumor growth inhibitory action of mice S180 sarcoma, the suppression ratio of present composition 10g/kg is 35.6%, the suppression ratio of 5-fluorouracil (5-FU) 12.5mg/kg is 13.1%, and the suppression ratio of present composition 10g/kg associating 5-fluorouracil (5-FU) 12.5mg/kg is 51.2%.The present invention treats leading indicator and all is better than the 5-fluorouracil group, has tumor inhibition effect preferably.
In sum, side's medicine of the present invention can be treated cardiomyopathy, femur head necrosis and inhibition tumor simultaneously.
The specific embodiment
1 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 50 Radix Panacis Quinquefoliis 30 Olibanums 10 Myrrhas 10 Eupolyphaga Seu Steleophagas 10 Os Draconis 10
Pyritum 5 artificial Moschuss 1 iron staff mallet 10 Pumexs 10 Indigo Naturaliss 5.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition may further comprise the steps:
(1) measures each component by prescription.
(2) from Olibanum, Myrrha, extract Olibanum volatile oil, Myrrha volatile oil respectively:
After respectively Olibanum, Myrrha being crushed to 100 orders, use petroleum ether dissolution, and, obtain Olibanum volatile oil, Myrrha volatile oil with the Petroleum ether extraction petroleum ether that in the water-bath fume hood, volatilizees again after colourless.
The mixture of Olibanum volatile oil and Myrrha volatile oil mixing back and beta-schardinger dextrin-and hydroxypropyl cellulose carries out inclusion by 8: 1 weight ratio to be fixed, obtain Olibanum-Myrrha clathrate, this Olibanum-Myrrha clathrate obtains relative density after concentrating be Olibanum-Myrrha extractum of 1～1.15.
Wherein the weight ratio of beta-schardinger dextrin-and hydroxypropyl cellulose is 1: 1.
(3) extract Pyritum and Pumex water-soluble extracting liquid:
Add the 100mL culture medium in 0.1g Pyritum coarse powder and 0.5g Pumex, and add antibacterial by the concentration of 3 * 108/mL, 10% inoculum concentration, making its pH value is 6.0～6.5; Be that 180r/min, temperature are to cultivate 15d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 20ml.
Wherein: culture medium is mixed by 1g potassium dihydrogen phosphate, 0.2g bitter salt, 1.3g dipotassium hydrogen phosphate, 0.02g calcium chloride, 1g ammonium nitrate, 0.1g three water iron chloride, 0.005g Zinc vitriol, 0.005g manganese sulfate, 0.005g bitter salt copper, 0.005g Sodium Molybdate Dihydrate, 0.1 gram Carnis Bovis seu Bubali cream, 0.3 gram peptone, 0.2 gram sodium chloride and 1L water.
Antibacterial is any one among achromobacter Achromobacter sp, Flavobacterium Flavobacterium sp, bacillus sp, the excellent bacillus Corynebacterium sp.
(4) extract the Indigo Naturalis water-soluble extracting liquid:
After Indigo Naturalis is crushed to 200 orders, carries out inclusion with the mixture of beta-schardinger dextrin-and hydroxypropyl cellulose by 8: 1 weight ratio again and fix, obtain the Indigo Naturalis inclusion complex; The weight ratio of beta-schardinger dextrin-and hydroxypropyl cellulose is 1: 1.
In 0.5g Indigo Naturalis clathrate, add the 100mL culture medium, and by 3 * 10
6The concentration of individual/mL, 5% inoculum concentration add antibacterial, and making its pH value is 5.5～6.0; Be that 200r/min, temperature are to cultivate 10d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with described extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 50ml;
Wherein: culture medium is that 20% Rhizoma Solani tuber osi liquor, 3g potassium dihydrogen phosphate, 1.5g magnesium sulfate, 20g glucose, 18g agar and 1L water mix by the 200mL mass concentration.
Antibacterial is any one among cunninghamella blakesleana Cunninghamella blakesleana.AS 3.153, Cunninghamella blakesleana.AS970, cunninghamella elegans Cunninghamella elegans.AS 3.2028, cunninghamella elegans Cunninghamella elegans.AS 3.156, the cunninghamella echinulata Cunninghamella echinulata AS 3.2004.
(5) extract Eupolyphaga Seu Steleophaga extractum:
It is that 85% ethanol carries out reflux, extract, 2 times that Eupolyph aga sinesis Walker is broken to behind 200 orders with mass concentration, is respectively 2h and 1h, obtains filtrate, and this filtrate concentrates through rotary evaporator that to obtain relative density after reclaiming ethanol be 1.15～1.35 Eupolyphaga Seu Steleophaga extractum.
(6) preparation Os Draconis, iron staff mallet water soluble ingredient extractum:
After Os Draconis, iron staff mallet are mixed, be in equipment for decocting Chinese traditional herb medicines, to decoct 3 times in 1: 3～1: 5, be followed successively by 3h, 2h, 1h by the feed liquid weight ratio, decoction liquor; Decoction liquor through centrifuge centrifugal filtration, again after vacuum concentration pan concentrates, is obtained relative density and is Os Draconis-iron staff mallet water soluble ingredient extractum of 1.15～1.25.
(7) Moschus, Radix Notoginseng, Radix Panacis Quinquefolii being ground to form particle diameter respectively is 200 purpose powder, and to Radix Notoginseng and Radix Panacis Quinquefolii ultraviolet disinfection.
(8) Os Draconis-iron staff mallet water soluble ingredient extractum of step (6) gained, the Olibanum-Myrrha extractum of step (2) gained, Pyritum and Pumex water-soluble extracting liquid, the Indigo Naturalis water-soluble extracting liquid of step (4) gained, the Eupolyphaga Seu Steleophaga extractum of step (5) gained of step (3) gained are mixed with the Moschus powder of step (7) gained and Notoginseng Root, the American Ginseng powder after the sterilization, obtain mixture; With this mixture routinely technology make tablet, capsule, granule, pill or electuary and get final product.
2 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 75 Radix Panacis Quinquefoliis 200 Olibanums 100 Myrrhas 50 Eupolyphaga Seu Steleophagas 150 Os Draconis 75
Pyritum 25 artificial Moschuss 2.5 iron staff mallets 75 Pumexs 60 Indigo Naturaliss 75.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
3 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 150 Radix Panacis Quinquefoliis 100 Olibanums 50 Myrrhas 100 Eupolyphaga Seu Steleophagas 75 Os Draconis 150
Pyritum 50 artificial Moschuss 5 iron staff mallets 150 Pumexs 120 Indigo Naturaliss 150.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
4 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 25 Radix Panacis Quinquefoliis 160 Olibanums 80 Myrrhas 30 Eupolyphaga Seu Steleophagas 130 Os Draconis 25
Pyritum 35 artificial Moschuss 1 iron staff mallet 60 Pumexs 80 Indigo Naturaliss 100.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
5 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 50 Radix Panacis Quinquefoliis 130 Olibanums 15 Myrrhas 15 Eupolyphaga Seu Steleophagas 30 Os Draconis 15
Pyritum 8 artificial Moschuss 3 iron staff mallets 20 Pumexs 15 Indigo Naturaliss 90.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
6 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 100 Radix Panacis Quinquefoliis 80 Olibanums 50 Myrrhas 50 Eupolyphaga Seu Steleophagas 80 Os Draconis 30
Pyritum 30 artificial Moschuss 1 iron staff mallet 80 Pumexs 50 Indigo Naturaliss 15.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
7 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 140 Radix Panacis Quinquefoliis 25 Olibanums 25 Myrrhas 15 Eupolyphaga Seu Steleophagas 20 Os Draconis 35
Pyritum 15 artificial Moschuss 4 iron staff mallets 30 Pumexs 20 Indigo Naturaliss 20.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
8 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 25 Radix Panacis Quinquefoliis 140 Olibanums 15 Myrrhas 25 Eupolyphaga Seu Steleophagas 35 Os Draconis 20
Pyritum 30 artificial Moschuss 4 iron staff mallets 15 Pumexs 15 Indigo Naturaliss 35.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
9 one kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 150 Radix Panacis Quinquefoliis 200 Olibanums 20 Myrrhas 20 Eupolyphaga Seu Steleophagas 120 Os Draconis 40
Pyritum 30 artificial Moschuss 2 iron staff mallets 50 Pumexs 10 Indigo Naturaliss 80.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
10 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 50 Radix Panacis Quinquefoliis 80 Olibanums 10 Myrrhas 10 Eupolyphaga Seu Steleophagas 60 Os Draconis 10
Pyritum 10 artificial Moschuss 1 iron staff mallet 10 Pumexs 30 Indigo Naturaliss 100.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
11 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 100 Radix Panacis Quinquefoliis 150 Olibanums 15 Myrrhas 15 Eupolyphaga Seu Steleophagas 100 Os Draconis 15
Pyritum 30 artificial Moschuss 1 iron staff mallet 30 Pumexs 15 Indigo Naturaliss 120.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
12 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 80 Radix Panacis Quinquefoliis 160 Olibanums 25 Myrrhas 25 Eupolyphaga Seu Steleophagas 80 Os Draconis 15
Pyritum 80 artificial Moschuss 1 iron staff mallet 20 Pumexs 50 Indigo Naturaliss 80.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
13 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 50 Radix Panacis Quinquefoliis 200 Olibanums 30 Myrrhas 35 Eupolyphaga Seu Steleophagas 130 Os Draconis 25
Pyritum 50 artificial Moschuss 2 iron staff mallets 30 Pumexs 100 Indigo Naturaliss 30.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
14 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 20 Radix Panacis Quinquefoliis 120 Olibanums 35 Myrrhas 25 Eupolyphaga Seu Steleophagas 50 Os Draconis 10
Pyritum 70 artificial Moschuss 1 iron staff mallet 10 Pumexs 60 Indigo Naturaliss 150.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
15 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 20 Radix Panacis Quinquefoliis 120 Olibanums 25 Myrrhas 15 Eupolyphaga Seu Steleophagas 50 Os Draconis 10
Pyritum 60 artificial Moschuss 1 iron staff mallet 10 Pumexs 60 Indigo Naturaliss 135.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
16 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 10 Radix Panacis Quinquefoliis 20 Olibanums 15 Myrrhas 15 Eupolyphaga Seu Steleophagas 150 Os Draconis 150
Pyritum 15 artificial Moschuss 3 iron staff mallets 150 Pumexs 15 Indigo Naturaliss 60.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
17 1 kinds of compositionss for the treatment of cardiomyopathy, femur head necrosis and tumor of embodiment, form by the following weight parts crude drug:
Radix Notoginseng 30 Radix Panacis Quinquefoliis 45 Olibanums 25 Myrrhas 35 Eupolyphaga Seu Steleophagas 45 Os Draconis 15
Pyritum 100 artificial Moschuss 10 iron staff mallets 35 Pumexs 35 Indigo Naturaliss 65.
The dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
The preparation technology of said composition is with embodiment 1.
Claims (7)
1. compositions for the treatment of cardiomyopathy, femur head necrosis and tumor, it is characterized in that: said composition is made up of the following weight parts crude drug:
Radix Notoginseng 10～150 Radix Panacis Quinquefoliis 20～200 Olibanums 10～100 Myrrhas 10～100
Eupolyphaga Seu Steleophaga 10～150 Os Draconis 10～150 Pyritums 5～100 artificial Moschuss 1～10
Iron staff mallet 10～150 Pumexs 10～120 Indigo Naturaliss 5～150.
2. the compositions of treatment cardiomyopathy as claimed in claim 1, femur head necrosis and tumor is characterized in that: the dosage form of said composition is a kind of in tablet, capsule, granule, pill, the electuary.
3. the preparation of compositions technology of treatment cardiomyopathy as claimed in claim 2, femur head necrosis and tumor may further comprise the steps:
(1) measures each component by prescription;
(2) from Olibanum, Myrrha, extract Olibanum volatile oil, Myrrha volatile oil respectively; The mixture of described Olibanum volatile oil and described Myrrha volatile oil mixing back and beta-schardinger dextrin-and hydroxypropyl cellulose carries out inclusion by 8: 1 weight ratio to be fixed, obtain Olibanum-Myrrha clathrate, this Olibanum-Myrrha clathrate obtains relative density after concentrating be Olibanum-Myrrha extractum of 1～1.15; The weight ratio of wherein said beta-schardinger dextrin-and described hydroxypropyl cellulose is 1: 1;
(3) extract Pyritum and Pumex water-soluble extracting liquid:
Add the 100mL culture medium in 0.1g Pyritum coarse powder and 0.5g Pumex, and add antibacterial by the concentration of 3 * 108/mL, 10% inoculum concentration, making its pH value is 6.0～6.5; Be that 180r/min, temperature are to cultivate 15d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with described extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 20ml;
Wherein said culture medium is mixed by 1g potassium dihydrogen phosphate, 0.2g bitter salt, 1.3g dipotassium hydrogen phosphate, 0.02g calcium chloride, 1g ammonium nitrate, 0.1g three water iron chloride, 0.005g Zinc vitriol, 0.005g manganese sulfate, 0.005g bitter salt copper, 0.005g water sodium molybdate, 0.1 gram Carnis Bovis seu Bubali cream, 0.3 gram peptone, 0.2 gram sodium chloride and 1L water;
(4) extract the Indigo Naturalis water-soluble extracting liquid:
After Indigo Naturalis is crushed to 200 orders, carries out inclusion with the mixture of beta-schardinger dextrin-and hydroxypropyl cellulose by 8: 1 weight ratio again and fix, obtain the Indigo Naturalis inclusion complex; The weight ratio of described beta-schardinger dextrin-and described hydroxypropyl cellulose is 1: 1;
In 0.5g Indigo Naturalis clathrate, add the 100mL culture medium, and by 3 * 10
6The concentration of individual/mL, 5% inoculum concentration add antibacterial, and making its pH value is 5.5～6.0; Be that 200r/min, temperature are to cultivate 10d in 30 ℃ the constant temperature shaking table at rotating speed then, obtain extracting solution; Is the filtering with microporous membrane of 0.45um with the aperture with described extracting solution behind sucking filtration, obtains filtrate, and concentrates this filtrate to 50ml;
Wherein said culture medium is that 20% Rhizoma Solani tuber osi liquor, 3g potassium dihydrogen phosphate, 1.5g magnesium sulfate, 20g glucose, 18g agar and 1L water mix by the 200mL mass concentration;
(5) extract Eupolyphaga Seu Steleophaga extractum:
Being broken to behind 200 orders Eupolyph aga sinesis Walker with mass concentration is after 85% ethanol carries out reflux, extract,, and to obtain relative density be 1.15～1.35 Eupolyphaga Seu Steleophaga extractum through concentrating;
(6) preparation Os Draconis, iron staff mallet water soluble ingredient extractum:
After Os Draconis, iron staff mallet are mixed, after decocting, filter, concentrating, obtain relative density and be Os Draconis-iron staff mallet water soluble ingredient extractum of 1.15～1.25;
(7) Moschus, Radix Notoginseng, Radix Panacis Quinquefolii being ground to form particle diameter respectively is 200 purpose powder, and to Radix Notoginseng and Radix Panacis Quinquefolii ultraviolet disinfection;
(8) Os Draconis-iron staff mallet water soluble ingredient extractum of described step (6) gained, the Olibanum-Myrrha extractum of described step (2) gained, Pyritum and Pumex water-soluble extracting liquid, the Indigo Naturalis water-soluble extracting liquid of described step (4) gained, the Eupolyphaga Seu Steleophaga extractum of described step (5) gained of described step (3) gained are mixed with the Moschus powder of described step (7) gained and Notoginseng Root, the American Ginseng powder after the sterilization, obtain mixture; With this mixture routinely technology make tablet, capsule, granule, pill or electuary and get final product.
4. the preparation of compositions technology of treatment cardiomyopathy as claimed in claim 3, femur head necrosis and tumor, it is characterized in that: after Olibanum volatile oil, the Myrrha volatile oil in the described step (2) is meant and respectively Olibanum, Myrrha is crushed to 100 orders, use petroleum ether dissolution, and with Petroleum ether extraction volatile oil of volatilization petroleum ether gained in the water-bath fume hood again after colourless.
5. the preparation of compositions technology of treatment cardiomyopathy as claimed in claim 3, femur head necrosis and tumor is characterized in that: the antibacterial in the described step (3) is any one in achromobacter, Flavobacterium, bacillus cereus, the excellent bacillus.
6. the preparation of compositions technology of treatment cardiomyopathy as claimed in claim 3, femur head necrosis and tumor is characterized in that: the antibacterial in the described step (4) is any one among cunninghamella blakesleana AS 3.153, cunninghamella blakesleana AS970, cunninghamella elegans AS 3.2028, cunninghamella elegans AS 3.156, the cunninghamella echinulata AS 3.2004.
7. the preparation of compositions technology of treatment cardiomyopathy as claimed in claim 3, femur head necrosis and tumor is characterized in that: the decocting condition of described step (6) is meant that the feed liquid weight ratio is 1: 3～1: 5, decocts 3 times, is followed successively by 3h, 2h, 1h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105515684A CN101991665B (en) | 2010-11-15 | 2010-11-15 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105515684A CN101991665B (en) | 2010-11-15 | 2010-11-15 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101991665A true CN101991665A (en) | 2011-03-30 |
| CN101991665B CN101991665B (en) | 2012-05-09 |
Family
ID=43782742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105515684A Expired - Fee Related CN101991665B (en) | 2010-11-15 | 2010-11-15 | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101991665B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
| US11033579B2 (en) | 2015-09-24 | 2021-06-15 | Innolife Co., Ltd. | Use of trientine to deliver copper to ischemic tissue |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156287C (en) * | 2000-10-24 | 2004-07-07 | 张景红 | A pharmaceutical composition for treating myocardial diseases |
-
2010
- 2010-11-15 CN CN2010105515684A patent/CN101991665B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156287C (en) * | 2000-10-24 | 2004-07-07 | 张景红 | A pharmaceutical composition for treating myocardial diseases |
Non-Patent Citations (3)
| Title |
|---|
| 《河南中医》 20040310 陈翠花等 中药在肿瘤治疗中的应用 74-75 1-7 , 第03期 2 * |
| 《河南中医学院学报》 20050420 申根雷等 中医综合治疗股骨头坏死临床分析 45-46 1-7 , 第02期 2 * |
| 《甘肃中医学院学报》 20020720 张景红等 伤肌宁胶囊的制备工艺研究 18-19 全文 , 第02期 2 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103285104A (en) * | 2013-05-14 | 2013-09-11 | 张景红 | Traditional Chinese medicine injection for repairing myocardial injury |
| CN103285104B (en) * | 2013-05-14 | 2016-01-06 | 张景红 | A kind of have the Chinese medicine injection repairing myocardial damage effect |
| US11033579B2 (en) | 2015-09-24 | 2021-06-15 | Innolife Co., Ltd. | Use of trientine to deliver copper to ischemic tissue |
| US12076340B2 (en) | 2015-09-24 | 2024-09-03 | Innolife Co., Ltd. | Use of trientine to deliver copper to ischemic tissue |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101991665B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127749A (en) | Traditional Chinese medicament for treating organic phosphorus pesticide poisoning and preparation method thereof | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN108619355A (en) | A kind of antitumor Chinese and preparation method thereof | |
| CN101991665B (en) | Composition for treating myocardial diseases, femoral head necrosis and tumor and preparation process thereof | |
| CN102772611B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN104958490A (en) | Medicine for treating qi stagnation and blood stasis type coronary heart diseases and method for manufacturing medicine | |
| CN100358568C (en) | Medicine for treating high blood pressure and its preparation method | |
| CN104069446A (en) | Traditional Chinese medicine composition for treating angina pectoris | |
| CN101129956B (en) | Traditional Chinese medicine for treating rickets | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN105412867A (en) | Chinese and western medicine for gynecology and obstetrics surgery and preparation method thereof | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN102008539B (en) | Medicinal composition for treating diseases such as viral myocarditis and dilated cardiomyopathy and preparation process thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN102908425A (en) | Medicine for treating heart diseases and thick blood lipid and preparation method of the medicine | |
| CN102293985A (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN105770745A (en) | Traditional Chinese medicine liquor for treating dyslipidemia and preparation method thereof | |
| CN105169099A (en) | Traditional Chinese medicine recovery formula for curing paraquat poisoning | |
| CN102309561B (en) | Pharmaceutical composition used for preventing and treating urarthritis and hyperuricemia | |
| CN104523861A (en) | Traditional Chinese medicine combination used for treating stroke and preparation method thereof | |
| CN103961655A (en) | Medicament for treating femoral head necrosis and preparation method thereof | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN103028094A (en) | Chinese patent medicine for treating coronary heart disease | |
| CN105343454A (en) | Traditional Chinese medicinal capsule for treating thrombus, and preparation method thereof | |
| CN106389702A (en) | Traditional Chinese medicine for recovering symptoms of gynecological and obstetric surgery and preparation method of traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 |